These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 2809728

  • 1. Murine intracerebral interleukin-2 injection: pathological and immunological effects.
    Yamasaki T, Kikuchi H, Paine JT, Yamashita J, Miyatake S, Iwasaki K, Kobayashi H, Namba Y, Hanaoka M.
    J Neurosurg; 1989 Nov; 71(5 Pt 1):732-40. PubMed ID: 2809728
    [Abstract] [Full Text] [Related]

  • 2. A morphological and ultrastructural investigation of normal mouse brain tissue after intracerebral injection of tumor necrosis factor.
    Yamasaki T, Kikuchi H, Moritake K, Nagao S, Iwasaki K, Paine JT, Kagawa T, Namba Y.
    J Neurosurg; 1992 Aug; 77(2):279-87. PubMed ID: 1625018
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 4. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 01; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 5. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R, Rosenberg SA.
    J Immunol; 1985 Dec 01; 135(6):4273-80. PubMed ID: 3877766
    [Abstract] [Full Text] [Related]

  • 6. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 01; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 7. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M.
    Cancer Res; 1990 Oct 15; 50(20):6708-15. PubMed ID: 2208137
    [Abstract] [Full Text] [Related]

  • 8. Recombinant IL 2 but not recombinant interferon-gamma stimulates both proliferation and IgM secretion in a Ly-1+ clone of neoplastic murine B cells (BCL1).
    Brooks KH, Vitetta ES.
    J Immunol; 1986 Nov 15; 137(10):3205-10. PubMed ID: 2945863
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM, Hank JA.
    Cancer J Sci Am; 1997 Dec 15; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [Abstract] [Full Text] [Related]

  • 10. Preparation and characterization of polyclonal and monoclonal antibodies against human interleukin 1 alpha (IL 1 alpha).
    Kasahara T, Mukaida N, Shinomiya H, Imai M, Matsushima K, Wakasugi H, Nakano K.
    J Immunol; 1987 Mar 15; 138(6):1804-12. PubMed ID: 3546497
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
    Silagi S, Schaefer AE.
    J Biol Response Mod; 1986 Oct 15; 5(5):411-22. PubMed ID: 3490544
    [Abstract] [Full Text] [Related]

  • 15. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen.
    Kuroda K, Yagi J, Imanishi K, Yan XJ, Li XY, Fujimaki W, Kato H, Miyoshi-Akiyama T, Kumazawa Y, Abe H, Uchiyama T.
    J Immunol; 1996 Aug 15; 157(4):1422-31. PubMed ID: 8759722
    [Abstract] [Full Text] [Related]

  • 16. Circumvention of the induction of resistance in murine experimental autoimmune thyroiditis by recombinant IL-1 beta.
    Nabozny GH, Kong YC.
    J Immunol; 1992 Aug 01; 149(3):1086-92. PubMed ID: 1634763
    [Abstract] [Full Text] [Related]

  • 17. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
    Jürgenliemk-Schulz IM, Renes IB, Rutgers DH, Everse LA, Bernsen MR, Den Otter W, Battermann JJ.
    Radiat Oncol Investig; 1997 Aug 01; 5(2):54-61. PubMed ID: 9303058
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunogene therapy as a treatment for malignant brain tumors in young mice.
    Glick RP, Lichtor T, Lin H, Tarlock K, Cohen EP.
    J Neurosurg; 2006 Jul 01; 105(1 Suppl):65-70. PubMed ID: 16871873
    [Abstract] [Full Text] [Related]

  • 20. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
    Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA.
    J Immunol; 1985 Aug 01; 135(2):1488-97. PubMed ID: 3891854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.